TY - JOUR
T1 - Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer
T2 - a pooled analysis
AU - Borghaei, H.
AU - Ciuleanu, T. E.
AU - Lee, J. S.
AU - Pluzanski, A.
AU - Caro, R. Bernabe
AU - Gutierrez, M.
AU - Ohe, Y.
AU - Nishio, M.
AU - Goldman, J.
AU - Ready, N.
AU - Spigel, D. R.
AU - Ramalingam, S. S.
AU - Paz-Ares, L. G.
AU - Gainor, J. F.
AU - Ahmed, S.
AU - Reck, M.
AU - Maio, M.
AU - O'Byrne, K. J.
AU - Memaj, A.
AU - Nathan, F.
AU - Tran, P.
AU - Hellmann, M. D.
AU - Brahmer, J. R.
N1 - Funding Information:
This work was supported by Bristol Myers Squibb . We thank the patients and families who made these trials possible, the investigators and clinical study teams who participated in the trials, and Dako, an Agilent Technologies company, for collaborative development of the PD-L1 IHC 28-8 pharmDx assay. Medical writing and editorial support for the development of this manuscript, under the direction of the authors, was provided by Ashvanti Valji of Caudex (London, UK), and Wendy Sacks, PhD, and Michele Salernitano, of Ashfield MedComms, an Inizio company, and funded by Bristol Myers Squibb.
Funding Information:
This work was supported by Bristol Myers Squibb (Princeton, NJ) and Ono Pharmaceutical Company Ltd. (Osaka, Japan) (no grant numbers).
Publisher Copyright:
© 2022
PY - 2023/2
Y1 - 2023/2
N2 - Background: First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival. Patients and methods: Data were pooled from four studies of first-line nivolumab plus ipilimumab in advanced NSCLC (CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012). Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. Landmark analyses of OS by response status at 6 months and by tumor burden reduction in responders to nivolumab plus ipilimumab were also assessed. Results: In the pooled population (N = 1332) with a minimum follow-up of 29.1-58.9 months, median OS was 18.6 months, with a 3-year OS rate of 35%; median PFS was 5.4 months (3-year PFS rate, 17%). Objective response rate was 36%; median duration of response was 23.7 months, with 38% of responders having an ongoing response at 3 years. In patients with tumor programmed death-ligand 1 (PD-L1) <1%, ≥1%, 1%-49%, or ≥50%, 3-year OS rates were 30%, 38%, 30%, and 48%. Three-year OS rates were 30% and 38% in patients with squamous or non-squamous histology. Efficacy outcomes in patients aged ≥75 years were similar to the overall pooled population (median OS, 20.1 months; 3-year OS rate, 34%). In the pooled population, responders to nivolumab plus ipilimumab at 6 months had longer post-landmark OS than those with stable or progressive disease; 3-year OS rates were 66%, 22%, and 14%, respectively. Greater depth of response was associated with prolonged survival; in patients with tumor burden reduction ≥80%, 50% to <80%, or 30% to <50%, 3-year OS rates were 85%, 72%, and 44%, respectively. No new safety signals were identified in the pooled population. Conclusion: Long-term survival benefit and durable response with nivolumab plus ipilimumab in this large patient population further support this first-line treatment option for advanced NSCLC.
AB - Background: First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival. Patients and methods: Data were pooled from four studies of first-line nivolumab plus ipilimumab in advanced NSCLC (CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012). Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. Landmark analyses of OS by response status at 6 months and by tumor burden reduction in responders to nivolumab plus ipilimumab were also assessed. Results: In the pooled population (N = 1332) with a minimum follow-up of 29.1-58.9 months, median OS was 18.6 months, with a 3-year OS rate of 35%; median PFS was 5.4 months (3-year PFS rate, 17%). Objective response rate was 36%; median duration of response was 23.7 months, with 38% of responders having an ongoing response at 3 years. In patients with tumor programmed death-ligand 1 (PD-L1) <1%, ≥1%, 1%-49%, or ≥50%, 3-year OS rates were 30%, 38%, 30%, and 48%. Three-year OS rates were 30% and 38% in patients with squamous or non-squamous histology. Efficacy outcomes in patients aged ≥75 years were similar to the overall pooled population (median OS, 20.1 months; 3-year OS rate, 34%). In the pooled population, responders to nivolumab plus ipilimumab at 6 months had longer post-landmark OS than those with stable or progressive disease; 3-year OS rates were 66%, 22%, and 14%, respectively. Greater depth of response was associated with prolonged survival; in patients with tumor burden reduction ≥80%, 50% to <80%, or 30% to <50%, 3-year OS rates were 85%, 72%, and 44%, respectively. No new safety signals were identified in the pooled population. Conclusion: Long-term survival benefit and durable response with nivolumab plus ipilimumab in this large patient population further support this first-line treatment option for advanced NSCLC.
KW - NSCLC
KW - dual immunotherapy
KW - ipilimumab
KW - nivolumab
UR - http://www.scopus.com/inward/record.url?scp=85146294288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146294288&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2022.11.006
DO - 10.1016/j.annonc.2022.11.006
M3 - Article
C2 - 36414192
AN - SCOPUS:85146294288
SN - 0923-7534
VL - 34
SP - 173
EP - 185
JO - Annals of Oncology
JF - Annals of Oncology
IS - 2
ER -